title: [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy].
abstract: The control of delayed emesis is very important in order to continue ambulatory chemotherapy. We performed retrospective study that examined the efficacy of preventive treatment (granisetron+dexamethasone+domperidone) for delayed emesis induced by FOLFOX4 chemotherapy for advanced and recurrent colorectal cancer. The subjects were 92 patients who underwent FOLFOX4 chemotherapy at the Cancer Institute Hospital of JFCR (group with preventive treatment: 50, group without preventive treatment: 42), and the observation period was set as the 1st-9th cycle. The complete nausea inhibition rate was 50.0% in the group with and 21.5% in the group without preventive treatment, showing a significantly higher inhibition rate in the former (p=0.0047). The complete vomiting inhibition rates were 86.0% and 66.7%, respectively, again showing a significantly higher inhibition rate in the former (p=0.015). On multivariate analysis (multiple logistic analysis), the development of nausea/vomiting and preventive treatment for delayed emesis were significantly associated, showing that the treatment was an independent preventive factor. All adverse reactions induced by preventive treatment were mild, suggesting no safety-related problem. These findings suggested the usefulness of preventive treatment with granisetron, dexamethasone, and domperidone for FOLFOX4 chemotherapy-induced delayed emesis.
authors: Department of Pharmacy, Cancer Institute Hospital, Tokyo 135-8550, Japan. takashi.yokokawa@jfcr.or.jp
authors: Takashi
authors: T
authors: Yokokawa
authors: Satoshi
authors: S
authors: Matsusaka
authors: Daigo
authors: D
authors: Shouji
authors: Hiroshi
authors: H
authors: Imada
authors: Eri
authors: E
authors: Nakamoto
authors: Kayoko
authors: K
authors: Kamisugi
authors: Wataru
authors: W
authors: Suzuki
authors: Takeshi
authors: T
authors: Shirai
authors: Gou
authors: G
authors: Takahashi
authors: Kazuyoshi
authors: K
authors: Kawakami
authors: Eiji
authors: E
authors: Shinozaki
authors: Mitsukuni
authors: M
authors: Suenaga
authors: Nobuyuki
authors: N
authors: Mizunuma
authors: Kiyohiko
authors: K
authors: Hatake
authors: Toshihiro
authors: T
authors: Hama
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D003907:Dexamethasone / Q000627:therapeutic use*; D004294:Domperidone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009944:Organoplatinum Compounds / Q000009:adverse effects; D012189:Retrospective Studies; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D003907:Dexamethasone; D004294:Domperidone; D005472:Fluorouracil; D017829:Granisetron; D002955:Leucovorin; D009944:Organoplatinum Compounds